At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 300 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)
In Brief
A Phase 2 clinical trial evaluating Placebo and Atorvastatin for Heart Failure. Completed, enrolled 300 participants across 4 sites in 2 countries.
Detailed Summary
This research study will test whether atorvastatin, a drug commonly prescribed for reducing cholesterol levels, can protect the heart during chemotherapy with doxorubicin. Atorvastatin is from a family of medications that are commonly called "statins"
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesCanada, United States
CollaboratorsDana-Farber Cancer Institute, Brigham and Women's Hospital
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartJan 2017
Primary CompletionSep 2022
Study CompletionOct 2023
TodayJul 2026
First PostedOct 24, 2016
Enrollment StartJan 13, 2017
Primary CompletionSep 16, 2022
Study CompletionOct 11, 2023
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 9.7 years ago
Interventions
Placebodrug
A pill taken once a day
Atorvastatindrug
A pill taken once a day